News

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Are at-home red light LED masks just a myth? Read more about the latest social media trend and discover how you should counsel your patients in the clinic.

In this episode, Liza O'Dowd, MD, discusses the 52-week data from the ICONIC clinical program of icotrokinra, the most recently approved oral peptide agent for psoriasis.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Review the latest FDA pediatric dermatology updates, including dupilumab for childhood CSU, secukinumab for teen HS, and new CHE and infant eczema topical filings.

An early look at the finalized print issue—featuring key data, clinical takeaways, and expert insights before it reaches your mailbox.

Explore top dermatology conferences and meetings in May 2026 and let us know which ones you'll be attending!

Dermatology Times is looking back on the top stories in dermatology from the month of April.

New sham-controlled trial finds niostem's at-home wearable using low-level electrical stimulation boosts hair density in men, with minimal adverse effects.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress, including laughter yoga, relationships, and mindset shifts

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress — from family time and fitness to emotional intelligence training and even Botox.

Learn more about the in-depth topics covered in the April 2026 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

A systematic review of 8 studies finds early evidence for microneedling plus exosome therapy across alopecia, aging, pigmentation, and scarring, but calls for larger trials.

This review of the latest dermatological studies includes insights on Vitamin B12's connection to hyperpigmentation, treatment modalities for female pattern hair loss, 0.5% timolol maleate eye drops for rosacea, and more.

Maria Hordinsky, MD, breaks down phase 3 data that show topical clascoterone boosts male pattern hair growth for 12 months, targeting follicles without systemic hormonal adverse effects.

Allergist and bestselling author Zachary Rubin, MD, joins host Renata Block, DMSc, MMS, PA-C, to debunk common allergy and atopic dermatitis myths and explore the immunology of the atopic march, cross-specialty collaboration, and more.

A new survey reveals the significant disconnect between dermocosmetic labeling and clinical reality. Explore more and vote in today's poll.

Weekly microneedling combined with daily topical 5% minoxidil produced statistically significant hair density gains in 40 women with female pattern hair loss.

Aclaris Therapeutics shares promising Phase 1a data for ATI-052, showing long-acting dual Th2 blockade, and advances ATI-2138 toward Phase 2b lichen planus studies.

The application is based on phase 3 UP-AA trial data showing significant hair regrowth in patients with severe alopecia areata.

Even nonadvanced forms of systemic mastocytosis can significantly impact patients’ quality of life, though new treatments are improving outcomes.

New research shows podiatry students struggle to spot psoriasis and eczema on darker skin, exposing dermatology training gaps and driving calls for inclusive teaching.

The deal would vault the combined company to 7th-largest biosimilar player globally, with direct implications for biologic access in dermatology.

Part A of Study '302' demonstrated statistically significant and clinically meaningful hair growth in men with androgenetic alopecia, with a favorable safety profile and no cardiac adverse events.

Learn how narcissistic traits and body dysmorphia could shape cosmetic dermatology visits, with red flags, screening tips, and safer patient care.

Combination therapy may be particularly beneficial for frontal hairline regrowth, a traditionally difficult area to treat.

FDA will review a supplemental New Drug Application for topical roflumilast to treat infant AD with supporting trial data showing rapid itch relief and clear skin gains from week 1.

Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.